Comparing the Efficacy of Remdesivir, Favipiravir, and Casirivimab and Imdevimab on Duration of Hospitalization and ICU Stay of Hospitalized COVID-19 Patients

Life Science Research Communications

  • Sahar Kmal Hegazy1Department of Clinical Pharmacy, Faculty of Pharmacy, Tanta University, Tanta, Al Gharbiyah, EGYPT.
  • Ahmed Hosny Hassan2Department of Clinical Pharmacy, Mansoura University Hospital, El Mansoura, Dakahlia, EGYPT.

Volume 1 Issue 1 Pages 21-30

DOI: 10.5530/lsrc.1.1.7

Abstract

**Objectives:** The coronavirus disease of 2019 (COVID-19) disease advances science’s ability to address this catastrophe. Additionally, there have been numerous therapeutic advances against COVID-19. Antibody combination against COVID-19, casirivimab and imdevimab, is used in antiviral therapy. Remdesivir and Favipiravir are the two antiviral medications typically used to treat COVID-19. The aim is to compare the effect of remdesivir, favipiravir, and casirivimab and imdevimab on the duration of hospital and ICU stay of COVID-19 patients. **Materials and Methods:** In this study, 265 COVID-19 patients with Polymerase Chain Reaction (PCR) confirmation and indications for antiviral medication were allocated into one of three groups in a ratio of (2:2:1) Remdesivir (REM group); Favipiravir (FAV group), and casirivimab and imdevimab (REG group) respectively. Single-blind non-Randomized Controlled Trial (non-RCT) was the study design. The study’s medication is owned by Mansoura University Hospital (MUH). Following ethical permission. The duration of the study was six months from November 2021 to March 2022. **Results:** Casirivimab and imdevimab decrease hospital and ICU stay than favipiravir and remdesivir. **Conclusion:** Although casirivimab and imdevimab lack activity against the omicron variant of COVID-19, they cause better clinical parameters than the standard antiviral drugs.

Keywords

  • COVID-19
  • Remdesivir
  • Favipiravir
  • Casirivimab and imdevimab
  • Antivirals
IJOPP

Loading…